lornoxicam and Acute-Coronary-Syndrome

To evaluate the clinical efficacy, safety, and effects of the nonsteroidal anti-inflammatory drug lornoxicam on inflammatory markers in non-ST-segment elevation acute coronary syndrome (NSTEACS).. Eighty-five patients with NSTESCS were enrolled in a prospective randomized study. They were divided into 2 groups: 1) patients received lornoxicam (8 or 12 mg/daily) for 15 days in addition to standard treatment and 2) controls. Cardiovascular outcomes and the levels of C-reactive protein (CRP), IL-6, and IL-10 were determined.. The lornoxicam group exhibited a significant reduction in CRP and a decrease in IL-6. There was also a significant increase in IL-10 levels in this group. A 6-month follow-up indicated a significant reduction in the number of cardiovascular events (nonfatal myocardial infarction, unstable angina, coronary death).. Lornoxicam reduces the risk of poor cardiovascular outcomes in patients with NSTEACS and the levels of inflammatory markers.

Topics: Acute Coronary Syndrome; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Interleukin-10; Interleukin-6; Male; Piroxicam; Prospective Studies; Treatment Outcome